O	0	3	Ten
O	3	4	-
O	4	8	year
O	9	15	follow
O	15	16	-
O	16	18	up
O	19	21	of
O	22	23	3
O	24	29	years
O	30	32	of
B-intervention	33	37	oral
I-intervention	38	46	adjuvant
I-intervention	47	57	clodronate
I-intervention	58	65	therapy
O	66	71	shows
O	72	83	significant
O	84	94	prevention
O	95	97	of
B-condition	98	110	osteoporosis
O	111	113	in
O	114	119	early
O	119	120	-
O	120	125	stage
O	126	132	breast
O	133	139	cancer
O	139	140	.

O	141	143	We
O	144	148	have
O	149	159	previously
O	160	168	reported
O	169	173	that
O	174	175	3
O	175	176	-
O	176	180	year
O	181	189	adjuvant
O	190	200	clodronate
O	201	210	treatment
O	211	219	prevents
O	220	224	bone
O	225	229	loss
O	230	232	in
O	233	239	breast
O	240	246	cancer
O	247	255	patients
O	255	256	.

O	257	261	Here
O	262	264	we
O	265	271	report
O	272	275	the
O	276	278	10
O	278	279	-
O	279	283	year
O	284	290	follow
O	290	291	-
O	291	293	up
O	294	298	data
O	299	301	of
O	302	312	clodronate
O	313	315	in
O	316	319	the
O	320	330	prevention
O	331	333	of
O	334	343	treatment
O	343	344	-
O	344	351	related
O	352	364	osteoporosis
O	365	367	in
O	368	373	women
O	374	378	with
O	379	384	early
O	384	385	-
O	385	390	stage
O	391	397	breast
O	398	404	cancer
O	404	405	.

B-total-participants	406	409	Two
I-total-participants	410	417	hundred
I-total-participants	418	423	sixty
I-total-participants	423	424	-
I-total-participants	424	429	eight
B-eligibility	430	433	pre
I-eligibility	433	434	-
I-eligibility	435	438	and
I-eligibility	439	453	postmenopausal
I-eligibility	453	454	,
I-eligibility	455	459	node
I-eligibility	459	460	-
I-eligibility	460	468	positive
I-eligibility	469	475	breast
I-eligibility	476	482	cancer
I-eligibility	483	491	patients
O	492	496	were
O	497	505	randomly
O	506	514	assigned
O	515	517	to
O	518	528	clodronate
O	528	529	,
O	530	531	1
O	531	532	.
O	532	533	6
O	534	535	g
O	536	542	orally
O	543	555	administered
O	556	561	daily
O	561	562	,
O	563	565	or
O	566	568	to
B-control	569	576	control
I-control	577	583	groups
O	584	587	for
O	588	589	3
O	590	595	years
O	595	596	.

O	597	610	Premenopausal
O	611	616	women
O	617	621	were
O	622	629	treated
O	630	634	with
O	635	643	adjuvant
O	644	647	CMF
O	648	660	chemotherapy
O	660	661	;
O	662	665	and
O	666	680	postmenopausal
O	681	686	women
O	687	691	were
O	692	699	treated
O	700	704	with
O	705	718	antiestrogens
O	718	719	,
O	720	726	either
O	727	729	20
O	730	732	mg
O	733	742	tamoxifen
O	743	745	or
O	746	748	60
O	749	751	mg
O	752	762	toremifene
O	762	763	,
O	764	767	for
O	768	769	3
O	770	775	years
O	775	776	.

O	777	780	The
O	781	785	bone
O	786	793	mineral
O	794	801	density
O	802	803	(
O	803	806	BMD
O	806	807	)
O	808	810	of
O	811	814	the
O	815	821	lumbar
O	822	827	spine
O	828	831	and
O	832	835	hip
O	836	839	was
O	840	848	measured
O	849	855	before
O	856	865	treatment
O	866	869	and
O	870	872	at
O	873	874	1
O	874	875	,
O	876	877	2
O	877	878	,
O	879	880	3
O	880	881	,
O	882	883	5
O	883	884	,
O	885	888	and
O	889	891	10
O	892	897	years
O	898	903	after
O	904	911	therapy
O	911	912	.

B-total-participants	913	919	Eighty
I-total-participants	919	920	-
I-total-participants	920	924	nine
O	925	932	disease
O	932	933	-
O	933	937	free
O	938	946	patients
O	947	951	were
O	952	960	included
O	961	963	in
O	964	967	the
O	968	976	analyses
O	977	979	of
O	980	992	osteoporosis
O	992	993	-
O	993	997	free
O	998	1006	survival
O	1006	1007	.

O	1008	1014	During
O	1015	1018	the
O	1019	1021	10
O	1021	1022	-
O	1022	1026	year
O	1027	1033	period
O	1033	1034	,
O	1035	1037	24
O	1038	1040	of
O	1041	1043	89
O	1044	1052	patients
O	1053	1057	were
O	1058	1067	diagnosed
O	1068	1072	with
O	1073	1085	osteoporosis
O	1085	1086	.

O	1087	1095	Fourteen
O	1096	1104	patients
O	1105	1114	developed
B-outcome	1115	1121	spinal
I-outcome	1122	1134	osteoporosis
O	1135	1136	(
B-iv-bin-abs	1136	1141	three
O	1142	1144	of
B-intervention-participants	1145	1147	41
O	1148	1150	in
O	1151	1154	the
O	1155	1165	clodronate
O	1166	1171	group
O	1171	1172	,
O	1173	1176	and
B-cv-bin-abs	1177	1179	11
O	1180	1182	of
B-control-participants	1183	1185	48
O	1186	1188	in
O	1189	1192	the
O	1193	1200	control
O	1201	1206	group
O	1206	1207	)
O	1207	1208	,
O	1209	1212	and
O	1213	1215	14
O	1216	1218	of
O	1219	1221	89
O	1222	1230	patients
O	1231	1235	were
O	1236	1245	diagnosed
O	1246	1250	with
B-outcome	1251	1254	hip
I-outcome	1255	1267	osteoporosis
O	1268	1269	(
B-iv-bin-abs	1269	1274	seven
O	1275	1277	of
B-intervention-participants	1278	1280	41
O	1281	1283	in
O	1284	1287	the
O	1288	1298	clodronate
O	1299	1304	group
O	1304	1305	,
O	1306	1309	and
B-cv-bin-abs	1310	1315	seven
O	1316	1318	of
B-control-participants	1319	1321	48
O	1322	1324	in
O	1325	1328	the
O	1329	1336	control
O	1337	1342	group
O	1342	1343	)
O	1343	1344	.

O	1345	1348	The
O	1349	1351	10
O	1351	1352	-
O	1352	1356	year
O	1357	1363	spinal
O	1363	1364	,
B-outcome	1365	1377	osteoporosis
I-outcome	1377	1378	-
I-outcome	1378	1382	free
I-outcome	1383	1391	survival
I-outcome	1392	1396	rate
O	1397	1400	was
B-iv-bin-percent	1401	1403	92
I-iv-bin-percent	1403	1404	.
I-iv-bin-percent	1404	1405	7
I-iv-bin-percent	1405	1406	%
O	1407	1409	in
O	1410	1413	the
O	1414	1424	clodronate
O	1425	1430	group
O	1430	1431	,
O	1432	1435	and
B-cv-bin-percent	1436	1438	77
I-cv-bin-percent	1438	1439	.
I-cv-bin-percent	1439	1440	0
I-cv-bin-percent	1440	1441	%
O	1442	1444	in
O	1445	1448	the
O	1449	1456	control
O	1457	1462	group
O	1463	1464	(
O	1464	1465	P
O	1466	1467	=
O	1468	1469	.
O	1469	1472	035
O	1472	1473	)
O	1473	1474	.

O	1475	1477	No
O	1478	1488	difference
O	1489	1492	was
O	1493	1497	seen
O	1498	1500	in
O	1501	1504	the
B-outcome	1505	1514	frequency
I-outcome	1515	1517	of
I-outcome	1518	1521	hip
I-outcome	1522	1534	osteoporosis
O	1535	1536	(
B-iv-bin-percent	1536	1538	85
I-iv-bin-percent	1538	1539	.
I-iv-bin-percent	1539	1540	4
I-iv-bin-percent	1540	1541	%
O	1542	1543	v
B-cv-bin-percent	1544	1546	82
I-cv-bin-percent	1546	1547	.
I-cv-bin-percent	1547	1548	9
I-cv-bin-percent	1548	1549	%
O	1549	1550	;
O	1551	1552	P
O	1553	1554	=
O	1555	1556	.
O	1556	1558	92
O	1558	1559	)
O	1559	1560	.

O	1561	1569	Baseline
B-outcome	1570	1573	BMD
O	1574	1585	measurement
O	1586	1589	had
O	1590	1591	a
O	1592	1602	predictive
O	1603	1608	value
O	1609	1611	of
O	1612	1614	18
O	1615	1617	of
O	1618	1620	24
O	1621	1629	patients
O	1630	1631	(
O	1631	1633	75
O	1633	1634	%
O	1634	1635	)
O	1636	1639	who
O	1640	1649	developed
O	1650	1662	osteoporosis
O	1663	1666	had
O	1667	1677	osteopenia
O	1678	1680	of
O	1681	1684	the
O	1685	1691	lumbar
O	1692	1697	spine
O	1698	1700	at
O	1701	1709	baseline
O	1709	1710	.

O	1711	1716	Three
O	1717	1722	years
O	1723	1725	of
O	1726	1736	clodronate
O	1737	1744	therapy
O	1745	1758	significantly
O	1759	1766	reduces
O	1767	1770	the
B-outcome	1771	1780	incidence
I-outcome	1781	1783	of
I-outcome	1784	1790	lumbar
I-outcome	1791	1796	spine
I-outcome	1797	1809	osteoporosis
O	1809	1810	.

O	1811	1819	Patients
O	1820	1822	at
O	1823	1827	risk
O	1828	1830	of
O	1831	1841	developing
O	1842	1854	osteoporosis
O	1855	1858	are
O	1859	1864	among
O	1865	1870	those
O	1871	1874	who
O	1875	1879	have
O	1880	1892	pretreatment
O	1893	1903	osteopenia
O	1903	1904	,
O	1905	1909	that
O	1910	1912	is
O	1912	1913	,
O	1914	1922	baseline
O	1923	1926	BMD
O	1927	1938	measurement
O	1939	1942	has
O	1943	1953	predictive
O	1954	1959	value
O	1959	1960	.
